fever (DHF)). Thus, T cell exhaustion plays a central role in determining outcome in autoimmune disease and targeted manipulation of this process could lead to new therapeutic opportunities.
In a complex set of data such as the transcriptome, similar measurements may be grouped together by network analysis to form discrete modules that can highlight novel pathways contributing to the pathogenesis of complex diseases. We have previously shown that a CD8 T cell transcriptional signature in patients with multiple immune-mediated diseases can predict a subsequent relapsing disease 2, 3 . However, the biology underlying this observation was not clear. We therefore applied weighted gene co-expression network analysis (Extended Data Fig. 1 ) 3 to the transcriptomes of purified CD4 and CD8 T cells isolated from a prospective cohort of 44 AAV patients with active, untreated disease 7 (Supplementary  Table 1 ) to further explore the mechanisms driving relapsing autoimmunity. Modules of genes (Fig. 1A , rows) were summarized as 'eigengene' profiles (Fig. 1B, F ) that were correlated with clinical variables (Fig. 1A, I , columns) and visualized in the form of a heatmap (Fig. 1A, I ). Modules derived from both CD8 (Fig. 1A-D) and CD4 ( Fig. 1 F-I ) T cell transcriptomes showed strong correlation with disease outcome but not activity, and were co-correlated ( Fig. 1E ) despite being mutually exclusive (Supplementary Table 2 ). A similar analysis using a cohort of 23 SLE patients also presenting with active, untreated disease (Supplementary Data Table 3 ) 2 identified analogous CD8 and CD4 T cell expression modules (Extended Data Fig. 2 ) that again correlated with clinical outcome but not disease activity. By contrast a type 1 interferon response signature was associated with disease activity but not with long-term outcome (Extended Data Fig. 2F ), consistent with previous reports 4 .
Next, we reasoned that genes within co-correlated modules in related cell types might inform the biology of relapsing disease. By selecting CD4 T cell modules showing significant, strong correlation with relapse rate and performing network enrichment analysis we identified a module corresponding to CD4 T cell costimulation (Extended Data Figs. 1F,  G, 3A, Supplementary Tables 2, 4) . By way of validation we repeated this analysis using an independent co-expression network algorithm that similarly demonstrated association between a CD4 costimulation module and clinical outcome (Supplementary Table 5 ). The independent association of modular signatures with clinical outcome (Fig. 1A, I ) was confirmed using multiple linear regression modeling (Extended Data Fig. 3B -E) and was only apparent during active disease (Extended Data Fig. 3F , Extended Discussion). During chronic viral infection CD8 T cell memory responses are exquisitely dependent on CD4 T cell costimulation 5, 6 which can lead to the resolution of chronic infection in both mice 1 and humans 7 . When antigen persists in the absence of costimulation CD8 T cells become 'exhausted' 1 , a phenotype characterized by progressive loss of effector function, persistent high expression of inhibitory receptors and profound changes in gene expression, distinct from those seen in effector, memory or anergic T cells 8 . Although mice lacking inhibitory receptors have an increased incidence and severity of autoimmunity 9,10 a specific role for exhaustion in dictating the outcome of autoimmune responses has not been demonstrated.
We hypothesized that CD4 T cell signals may be important in limiting exhaustion towards persistent self-antigen during autoreactive immunity, analogous to responses during persistent infection. We therefore used Gene Set Enrichment Analysis (GSEA 11 ) to test for altered expression of transcriptional signatures reflecting T cell exhaustion (and other T cellrelated phenotypes) between patient subgroups defined by the CD8 modular analysis, who go on to develop relapsing or quiescent autoimmunity (Fig2A). Using this approach, we observed that genes specifically downregulated in exhausted CD8 T cells during chronic murine LCMV infection (but not altered in memory, naïve or effector cells, Supplementary Table 6 8 ) were similarly downregulated in CD8 T cells from patients at low risk of subsequent relapse (Fig2B, Extended Data Figs. 3G-I, 4).
During chronic murine LCMV infection, T cell exhaustion is driven by coordinate upregulation of multiple coinhibitory receptors 12 that signal synergistically to produce a state of generalized immunosuppression 13 . In autoimmunity, these receptors were not coordinately upregulated as a group. Instead patients with good prognosis from each disease were characterized by upregulation of a distinct subset of exhaustion-associated coinhibitory receptors (Fig2C). Although a divergence from the murine LCMV model, T cell exhaustion accompanied by expression of a limited subset of coinhibitory receptors is similar to that described in intratumoral CD8 T cells 14 which are a target for checkpoint therapy (Extended Data Fig.4I ) 15, 16 .
To confirm whether exhaustion was associated with clinical outcome, we used the murine CD8 T cell exhaustion signature (Supplementary Table 6 (Fig. 2E , H, K) and recurrent (Fig. 2F, I , L) relapses. Whereas CD8 exhaustion was associated with poor outcome in viral infection, in every case it predicted favorable prognosis in autoimmune and inflammatory disease (Fig.2D-L) . Again, independent association with outcome was confirmed using multiple linear regression models (Extended Data Fig.3D, E) . Together, these data demonstrate that a transcriptional signature of relative CD8 T cell exhaustion, similar to that determining outcome in chronic viral infection and cancer, is apparent during active, untreated disease in patients with favorable long-term outcome in multiple autoimmune and inflammatory diagnoses.
CD8 T cell exhaustion is characterized by high expression of coinhibitory receptors (such as PD-1 12 ) and low expression of nascent memory markers (such as IL7R 17 ) and is promoted by both the persistence of antigen 18 and a lack of accessory costimulation 6 . To understand signals driving exhaustion and outcome in autoimmunity, we attempted to recreate the outcome-associated transcriptional signatures using variable TCR signal duration and costimulation of primary human cells in vitro. We stimulated purified human CD8 T cells using a magnetic bead conjugated with antibodies targeting costimulatory molecules (Fig.  3A) and measured expression of IL7R and PD-1 expression (Fig. 3B-I, Extended Data Fig.  5A -G) as markers indicating an exhausted phenotype. Comparison between persistent (6 days) and transient TCR stimulation (36 hours) showed that IL7R expression returned on a proportion of cells after several divisions when the TCR stimulus was removed (Fig. 3C ) but failed to do so if it persisted (Fig. 3D, G ). We then systematically tested whether costimulatory molecules, identified from the CD4 T cell network analysis described above (Fig.1I , Extended Data Figs. 3A, H-K), could overcome the effect of persistent TCR stimulation during in vitro differentiation. We found that specific costimulation with anti-CD2 (Fig. 3E, H ), but not with other stimuli such as IFNα or anti-CD40, resulted in maintained IL7R expression, limited upregulation of PD-1 and enhanced cell survival ( While CD8 exhaustion is known to limit viral control during chronic infection, exhausted cells may be restored to useful function by blocking inhibitory signaling through PD-1 19 . Enhancing coinhibitory signals is therefore a logical therapeutic strategy in autoimmune disease, aiming to facilitate exhaustion despite high levels of costimulation that would otherwise be predicted to result in an aggressive relapsing disease course. To test this concept, primary human CD8 T cells were costimulated during persistent TCR signaling as above (Fig. 3E) in the presence or absence of a bead-bound Fc-chimeric version of the principal PD-1 ligand, PDL-1 (Fig. 3A, F) . When added to CD2-costimulated CD8 T cell cultures, increased PD-1/PDL-1 signaling suppressed differentiation of a non-exhausted IL7R hi subpopulation (Fig.3 F, H, I ).
To define the phenotype of T cell exhaustion more robustly, as small numbers of surface markers are insufficient, we analyzed the transcriptome of CD8 T cells exposed to persistent stimulation with and without CD2 signaling (Supplementary Table 7 ). This CD2 response signature characterized exhausted cells but not effector or memory subsets (by GSEA, Fig.  3J -L). Consistent with this, patient clusters generated using the CD2 response signature recreated subgroups similar to those generated using the murine LCMV CD8 exhaustion signature (Fig. 2D , G, J and Fig. 3M-O) . Thus, CD2 signaling during persistent TCR stimulation of primary human CD8 T cells prevents the development of transcriptional changes characteristic of exhaustion, recreating transcriptional signatures associated with outcome in both viral infection and autoimmunity.
To confirm that the transcriptional signatures reflected the development of functional exhaustion in vitro, we showed that cells appearing exhausted by surface markers (IL7R lo PD-1 hi ) also expressed markers of apoptotic resistance, characteristic cytokine patterns and showed diminished survival on restimulation (BCL2 lo IFNγ lo IL10 hi , Extended Data Fig. 6A-E) . There was no evidence of preferential accumulation of CD8 T cell subsets following CD2-induced costimulation (Extended Data Fig. 6F-H) . These data highlight the importance of CD2 signaling in limiting the development of CD8 T cell exhaustion in the face of persistent TCR simulation, and provide a starting point for more sophisticated attempts to therapeutically exhaust an autoimmune response in a targeted fashion.
We next aimed to independently validate the association between the balance of CD4 costimulation and CD8 exhaustion with clinical outcome using published datasets. The majority of these profile unseparated peripheral blood mononuclear cells (PBMC), in which T cell-intrinsic signatures are not readily apparent due to the confounding influence of expression from other cell types 20 . We therefore used a classification algorithm (randomforests) to identify optimal surrogate markers of costimulation/exhaustion modules in PBMC data from autoimmune patients taken concurrently with the T cells described above (Fig. 4A) . As the CD8 exhaustion and CD4 costimulation signatures were themselves correlated (Extended Data Fig. 3G-I) , it became easier to detect their combined signal in PBMC using surrogate markers (Fig.4A, Extended Data Fig.7) . The top-ranked candidate KAT2B is a transcriptional co-activator known to mediate an anti-apoptotic effect under conditions of metabolic stress 52 and to increase cellular resistance to cytotoxic compounds 53 . These characteristics, along with its high expression in memory and Tfollicular helper and NK cells (Extended Data Fig. 8 ), suggest that it may mark the development of a durable, persistent T cell phenotype promoting long-lived responses in either infection or autoimmunity. The observed association was confirmed by both technical replication (using the same samples run on an independent array platform) and independent validation (Fig. 4B) .
To test whether similar associations may be apparent in multiple infectious and autoimmune diseases we directly compared expression levels of KAT2B (and of the other top surrogate markers, Extended Data Fig. 9 ) between clinical subgroups defined within published studies for which PBMC expression and linked clinical outcome data were available. Where subgroups were not pre-specified, we compared clinical outcome in groups stratified as having either above or below-median expression of KAT2B ( Fig. 4C-K) . Hierarchical clustering using all top surrogate markers gave similar stratification to that seen using KAT2B alone, while as expected the separation of patient subgroups varied slightly in different clinical circumstances ( Combined interferon and ribavirin therapy may result in increased virus-specific T cell responses in chronic HCV, although such eradication therapy is successful in only 50% of cases 21 and in some cases no change in endogenous immune response is observed 22 . In a cohort of hepatitis C patients receiving combination therapy, KAT2B expression was progressively induced and showed significantly greater induction in patients ultimately responding to therapy (Fig. 4C, Extended Data Fig. 10A ). In a clinical trial of malaria vaccination 23 high KAT2B expression identified a subgroup with response rates of 78%, almost twice that seen in the low response group (Fig. 4D, Extended Data Fig. 10B-D) . Moreover, response to vaccination for either influenza 24 (Fig. 4E, Extended Data Fig. 10E -F) or yellow fever 25 (Fig. 4F) could be predicted by stratifying recipients based on their expression of KAT2B following vaccine exposure. Dengue viral infection can result in a wide range of clinical manifestations ranging from asymptomatic infection or self-limiting fever (uncomplicated dengue, UD) to hemorrhagic fever (DHF). Consistent with our observations in autoimmunity, we observed that KAT2B expression was elevated in patients developing the excessive inflammatory response of DHF (Fig. 4G) 26 .
We next asked whether surrogate detection of T cell costimulation/exhaustion modules could predict progression of other autoimmune diseases. Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by both autoantibodies and autoreactive CD4 T cells 27 . In a cohort of 75 IPF patients 28 high expression of KAT2B predicted subsequent progression to transplantation or death (Fig. 4H) . We also observed that PBMC Kat2b expression was elevated in the murine NOD model of T1D 29 with levels rising sharply during the T cell initiation phase, long before the onset of diabetic hyperglycemia (Extended Data Fig. 10G ). In a cohort of samples taken prospectively from children at high risk of disease but prior to its onset 30 expression of KAT2B was seen to specifically and progressively rise (Fig. 4I-K) both in patients who progressed to T1D and in those who developed islet-cell autoantibodies.
We show that the balance between costimulatory and coinhibitory signals that shape T cell exhaustion coincide with opposite clinical outcomes during autoreactive and anti-viral immunity. This at once allows prediction of outcome during infection and autoimmunity and creates the potential for targeted therapeutic exhaustion of an autoimmune response in those predicted to follow an aggressive disease course. That this association is apparent in multiple autoimmune and inflammatory diseases emphasizes the importance of signals shaping T cell exhaustion in driving risk of relapse or recurrence (prognosis) rather than disease susceptibility (diagnosis) or immediate severity (disease activity), and suggests that targeted manipulation of these processes may lead to new treatment strategies that extend beyond the conditions discussed here.
Methods

Patients Ethical approval-Ethical approval for this study was obtained from the Cambridge Local Research
Ethics Committee (REC reference numbers 04/023, 08/H0306/21,08/H0308/176) and informed consent was obtained from all subjects enrolled.
AAV patients
59 AAV patients attending or referred to the specialist vasculitis unit at Addenbrooke's hospital, Cambridge, UK between July 2004 and May 2008 were enrolled into the present study. Active disease at presentation was defined by Birmingham vasculitis activity score (BVAS 31 ) and the clinical impression that induction immunosuppression would be required. Prospective disease monitoring was undertaken monthly with serial BVAS disease scoring 31 and full biochemical, hematological and immunological profiling followed by treatment with an immunosuppressant and tapering dose steroid therapy (Supplementary Table 1 ). At each time-point of follow-up, disease activity was allocated into one of three categories defined as follows:
1. Flare (at least 1 major or 3 minor BVAS criteria), 2. low grade activity (0 major and 1-2 minor BVAS criteria),
no activity (0 major or minor BVAS criteria).
All disease flares were crosschecked against patient records to confirm clinical impression of disease activity and the need for intensified therapy as a result. Disease activity scoring was performed by a single investigator (EFM) who was blinded to gene expression data at the time of scoring. Additional flares were defined in the absence of BVAS scoring if patients attended for emergency investigation (bronchoscopy, or specialist ophthalmological or Ear/Nose/Throat surgical review) that confirmed evidence of active disease. To differentiate between discrete flares, clear improvement in disease activity was required in the form of an improvement in flare-related symptoms together with a reduction in BVAS score, a reduction in markers of inflammation (CRP, ESR), and a reduction in immunosuppressive therapy.
SLE patients
The SLE cohort was composed of 23 patients attending or referred to the Addenbrooke's Hospital specialist vasculitis unit between July 2004 and May 2008 meeting at least four ACR SLE criteria 32 , presenting with active disease (defined below) and in whom immunosuppressive therapy was to be commenced or increased. Following treatment with an immunosuppressant patients were followed up monthly. Disease monitoring was undertaken with serial BILAG disease scoring 33 and full biochemical, hematological and immunological profiling (Supplementary Table 4 ).
A discrete disease flare required all three of the following prospectively defined criteria:
new BILAG score A or B in any system
2. clinical impression of active disease by the reviewing physician 3. the intention to increase in immunosuppressive therapy as a result.
Additional flares were defined in the absence of BILAG scoring if patients were admitted directly to hospital as emergency cases for increased immunosuppressive therapy. To differentiate between disease flares clear improvement in disease activity was required in the form of diminished flare-related symptoms together with a reduction in both BILAG score and immunosuppressive therapy.
IBD patients
Patients with active CD and UC were recruited from a specialist IBD clinic at Addenbrooke's Hospital, prior to commencing treatment. Diagnosis was made using standard endoscopic, histologic, and radiological criteria 34 . Patients who had already received immunomodulators or corticosteroids were excluded. Enrolled patients were managed conventionally using a step-up strategy 3 .
Assessment of disease activity was in accordance with national and international guidelines and included consideration of symptoms, clinical signs, and objective measures, including blood tests (C-reactive protein [CRP] , erythrocyte sedimentation rate [ESR], hemoglobin concentration, and serum albumin), stool markers (calprotectin), and mucosal assessment (by sigmoidoscopy or colonoscopy) where appropriate. Validated scoring tools were used as another means of assessing disease activity (Harvey-Bradshaw severity index 35 or simple clinical colitis activity index 36 for CD and UC, respectively), although these were not used to guide treatment decisions. All clinicians were blinded to the microarray results.
For each disease, all patients were not included in all analyses as, for example, comparison of modular network analysis in related cell types required that samples passing QC filtering were available for all cell types for all patients. Our previous publications have shown that the sample sizes used here are adequate to detect reproducible signatures correlating with clinical traits.
Follow up Analysis
Comparisons of outcome and associated clinical variables between subgroups were analyzed using the Kaplan-Meier log-rank test and non-parametric Mann Whitney U test or the Chisquare test as appropriate. Correction for multiple testing was applied using the Bonferroni method or false discovery rate (FDR, Benjamini and Hochberg method) where appropriate as indicated.
Cell separation and RNA extraction
Venepuncture was performed at a similar time of day in all cases to minimize gene expression differences arising from circadian variation 37 . Peripheral blood mononuclear cells (PBMC), CD4 and CD8 T cells were isolated from 110ml of whole blood by centrifugation over ficoll and positive selection using magnetic beads as previously described 20 . The purity of separated cell subsets was determined by flow cytometry and included as a covariate in downstream correlation and network analyses (e.g. Figure. 1 A, I ). Total RNA was extracted from each cell population using an RNeasy mini kit (Qiagen) with quality assessed using an Agilent BioAnalyser 2100 and RNA quantification performed using a NanoDrop ND-1000 spectrophotometer.
Microarray gene expression profiling
HsMediante25k custom spotted microarray-Total RNA (250 ng) was converted into double-stranded cDNA and labelled with Cy3-or Cy5-dCTP as previously described 20 . Appropriate Cy3-and Cy5-labelled samples were pooled and hybridized to custom spotted oligonucleotide microarrays (HsMediante25k) comprised of probes representing 25,342 genes and control features 38 . All samples were hybridized in duplicate, using a dye-swap strategy, against a common reference RNA derived from pooled PBMC samples. Following hybridization, arrays were washed and scanned on an Agilent G2565B scanner.
Affymetrix Human Gene 1.0 ST microarray-Aliquots of total RNA (200ng) were labeled using Ambion WT sense Target labeling kit and hybridized to Human Gene 1.0 or 1.1 ST Arrays (Affymetrix) as described. After washing, arrays were scanned using a GS 3000 or Gene Titan scanner (Affymetrix) as appropriate.
Published datasets
Published datasets were accessed through either NCBI-GEO or ArrayExpress, imported into R using the Bioconductor package GEOquery and analyzed as described. Search criteria incorporated the name of individual diseases and were filtered to human datasets but not by platform used. Studies were only included if they met the following criteria:
1. Similar QC filters as applied to the data produced in-house were satisfied (described below).
2.
Samples were taken at an analogous time-point to those from which the costimulation and exhaustion signatures in autoimmunity were identified. i.e. samples taken during active disease without concurrent immunosuppressive therapy.
3. Clinical outcome data was available.
It was not feasible to build a unified predictive model across all available datasets as they originated from different groups and were performed on mutually incompatible microarray platforms.
For the HCV data used in Fig. 4C a marked response was defined as an HCV titer decrease > 3.5 log10iu/ml and a poor response as an HCV titer decrease <1.5 log10iu/ml by day 28 after commencing combined therapy with ribavirin and pegylated interferon-alpha. For the Malaria vaccine trial used in Fig. 4D 'protection' was defined as delayed or complete protection from subsequent confirmed P.Falciparum infection following standardised exposure (x5 bites) compared to infectivity control subjects. For the influenza data used in Fig. 4E protection was defined as >/= 1 high response to at least 1 (of 3) included strains. A high response was defined as >/= 4-fold increase in HAI titre at d28 and a titre >/= 1:40 as per US FDA guidelines.
All gene expression data used has been deposited in publicly available repositories (NCBI-GEO and ArrayExpress): AAV, SLE (E-MTAB-2452, E-MTAB-157, E-MTAB-145) IBD (E-MTAB-331), LCMV (GSE9650), HCV (GSE7123), malaria vaccination (GSE18323), influenza vaccination (GSE29619), yellow fever vaccination (GSE13486), dengue fever (GSE25001), IPF (GSE28221), T1D (E-TABM-666), NOD (GSE21897), RA (GSE15258, GSE33377), in vitro CD8 stimulation (XXXX).
Data analysis
Preprocessing and quality control (QC)-For Mediante hs25k arrays, raw image data were extracted using Koadarray v2.4 software (Koada Technology) and probes with a confidence score >0.3 in at least one channel were flagged as present. Extracted data were imported into R where log transformation and background subtraction were performed followed by within array print-tip Loess normalization and between-array quantile and scale normalization using the Limma package 39 in Bioconductor 40 . Further analysis was then performed in R and only data demonstrating a strong negative correlation (r 2 >0.9) between dye swap replicates were used in downstream analyses.
Affymetrix raw data (.CEL) files were imported into R and subjected to variance stabilization normalization using the VSN package in BioConductor 41 . Quality control was performed using the Bioconductor package arrayQualityMetrics 42 with outlying samples removed from downstream analyses. Correction for batch variation was performed using the Bioconductor package ComBat 43 and batch structure was included as a covariate in downstream correlation analyses.
Clustering
Hierarchical clustering was performed using a Pearson correlation distance metric and average linkage analysis, performed either in Cluster with visualization in Treeview 44 , using Genepattern 45 or directly in R using hclust in the stats package.
Differential expression
Differentially-expressed genes were identified using linear modeling and an empirical Bayes method 39 using a false discovery rate threshold of 0.05 as indicated to determine significance.
Weighted Gene Coexpression Network Analysis (WGCNA)
Highly correlated genes in immune cell subsets were identified and summarized with a modular eigengene profile using the Weighted Gene Coexpression Network Analysis (WGCNA) Bioconductor package in R 46 . Normalized, log transformed expression data was variance filtered using the inflexion point of a ranked list of median absolute deviation values for all probes. A soft thresholding power was chosen based on the criterion of approximate scale-free topology 47 . Gene networks were constructed and modules identified from the resulting topological overlap matrix with a dissimilarity correlation threshold of 0.01 used to merge module boundaries and a specified minimum module size of n=30.
Modules were summarized as a network of modular eigengenes, which were then correlated with a matrix of clinical variables and the resulting correlation matrix visualized as a heatmap (Extended Data Figure 1 ). As each module by definition is comprised of highly correlated genes, their combined expression may be usefully summarized by eigengene profiles 48 , effectively the first principal component of a given module (e.g. Figure 1B, F) . A small number of eigengene profiles may therefore effectively 'summarize' the principle patterns within the cellular transcriptome with minimal loss of information. This dimensionality-reduction approach also facilitates correlation of ME with clinical traits (e.g. Figure 1A , I). Significance of correlation between a given clinical trait and a modular eigengene was assessed using linear regression with Bonferroni adjustment to correct for multiple testing (Extended Data Figure 1 ). Independent association of a given module eigengene or gene expression profile (e.g. KAT2B) with clinical outcome was assessed using a multiple linear regression model. Significance of each term in the linear model was plotted against its regression coefficient, as a measure of the strength of association (the regression coefficient reflecting the change in clinical outcome per unit change in modular/ gene expression), for example Extended Data Fig.3B -E.
Overlap of signatures with modules derived from network analysis is shown to the right of selected module heatmaps ( Figure 1A , Extended Data Figures 2A, E, F) by the following formula to allow correction for variable module size: (signature genes overlapping with module genes, n)/(genes in module, n) x100. The overlap of randomly selected signatures of equivalent size was used as a control and is shown adjacent to the above plots.
HOPACH analysis
For validation purposes, highly-correlated genes were independently partitioned into discrete modules using a second algorithm, Hierarchical Ordered Partitioning And Collapsing Hybrid (HOPACH 49 ) in R. This approach differs from WGCNA in that it does not rely on a user-specified correlation threshold to define module boundaries but rather aims to maximize homogeneity of modules. Normalized, log transformed data were clustered using a hierarchical algorithm with modular boundaries defined by the median split silhouette (MSS), a measure of how well-matched a gene is to the other genes within its current cluster versus how well-matched it would be if it were moved to another cluster. On partitioning the dataset into clusters, each cluster is reiteratively subdivided until the MSS is maximized, thereby producing an optimal segregation into maximally discrete modules.
Knowledge-based network generation and pathway analysis
The biological relevance of gene groups comprising modules identified by co-expression analysis were further investigated using the Ingenuity Pathways Analysis platform 50 . Six modules from the CD4 T cell WGCNA analysis showed significant correlation with clinical outcome in AAV after correction for multiple testing (Bonferroni method, Supplementary Table 3 ). We applied network and pathway enrichment analysis to genes comprising these modules to determine whether they may have any biological relevance. Briefly, for network analysis genes from a specified target set of interest are progressively linked together based on a measure of their interconnection, which is derived from described functional interactions. Additional highly interconnected genes that are absent from the target genes (open symbols) may be added to complete a network of arbitrary size (set at n = 35). Networks may be ranked by significance which reflects the probability of randomly generating a network of similar size from genes included in the full knowledge database containing at least as many target genes as in the network in question. For pathways analysis, the overrepresentation of canonical pathways (pre-defined, well-characterized metabolic and signaling pathways curated from extensive literature reviews) amongst a specified set of target genes is assessed, with significance determined by computing a Fisher's exact test with false discovery rate correction for multiple testing.
Gene Set Enrichment Analysis (GSEA)
GSEA 11 was used to further assess whether specific biological pathways or signatures were significantly enriched between patient subgroups identified by gene modules (as opposed to testing for enrichment of pathways within modules themselves as outlined in the previous section). GSEA determines whether an a priori defined 'set' of genes (such as a signature) show statistically significant cumulative changes in gene expression between phenotypic subgroups (such as patients with relapsing or quiescent disease). In brief, all genes are ranked based on their differential expression between two groups then an enrichment score (ES) is calculated for a given gene set based on how often its members appear at the top or bottom of the ranked differential list. 1000 random permutations of the phenotypic subgroups were used to establish a null distribution of ES against which a normalized enrichment score (NES) and FDR-corrected q values were calculated. GSEA was run with a focused subgroup of gene signatures (as in Figure 2B and Figure 3K ) 11 selected to test the null hypothesis that different CD8 T cell phenotypes were not significantly enriched in patient subgroups identified by modular analysis.
Selection of optimal PBMC-level biomarkers
Optimal surrogate markers facilitating identification of the CD4 T cell co-stimulation/CD8 exhaustion signatures in PBMC-level data were determined using a randomforests classification algorithm 51 ( Figure 4A ). Although signatures apparent in purified T cell transcriptome data correlate with clinical outcome, they cannot be similarly detected in data derived from PBMC due to the confounding influence of expression from other cell types nor can the same genes be used to predict outcome in PBMC 2, 20 . However, as CD4 T cell co-stimulation and CD8 T cell exhaustion signatures themselves showed close correlation we hypothesized that this would amplify the signal detectable in PBMC and that detection of the combined CD4/CD8 T cell response may be feasible. The availability of both separated T cell and PBMC data from the same patients at the same time facilitate a supervized search for surrogate markers of the co-stimulation/exhaustion signatures in PBMC. Expression data derived from both CD4 T cells and PBMC were available for a cohort of n=37 patients (AAV and SLE) following QC and hybridization to the HsMediante25k custom microarray platform and constituted a training cohort. Normalized, log-transformed expression data was analyzed using the MLInterfaces Bioconductor package in R 52 . Using PBMC-level expression data samples were classified into subgroups showing either high or low expression of the costimluation/exhaustion signature (as illustrated in Extended Data Figure  5H , I) and probes were subsequently ranked using the variable importance metric based on their ability to predict allocation to either group. The variable importance for a given gene reflects the change in accuracy of classification (% increase in MSE or increase in node purity) when that variable is randomly permuted. For a poorly predictive gene, random permutation of its values will minimally influence classification accuracy. Conversely, the most robust predictors will have a comparatively large effect on classification accuracy when randomly permuted. PBMC samples from a subset of n=37 cases derived from the training cohort were labeled and hybridized on an alternative microarray platform (Affymetrix Gene ST1.0) as a technical validation set ( Figure 4B , left panel). PBMC samples from an independent n=47 cases not included in the training cohort were labeled and hybridized to the Affymetrix Gene ST1.0 platform as an independent test set ( Figure  4B , right panel). For both technical validation and independent test sets expression of the optimal biomarker identified in Figure 4A (KAT2B) was used to bisect the cohort relative to the median expression and clinical outcome was compared in KAT2Bhi and KAT2Blo patients.
Linear Models
Linear modeling was performed in R using the stats package. This took the form of where y (the response variable) was selected as normalized flare rate (flares/days follow-up) and x 1 -x n (the test variables) were selected to include measures of disease activity (both clinical scores and laboratory markers of inflammation), quantification of circulating leucocyte subsets (lymphocytes, neutrophils) and concurrent measurements of autoantibody titer where relevant. Test variables also included a biomarker profile (e.g. exhaustion signature or KAT2B expression). The significance and magnitude (regression coefficient, reflecting change in response variable (flares/days follow-up) per unit change in each test variable included) were extracted and plotted against each other (for example, Extended Data Fig. 3B-E) . Not all clinical or laboratory measures were relevant comparisons in each case and therefore were not all included in every model generated.
T cell culture
Primary human CD8 T cells were separated from leucocyte cones obtained from NHS Blood and Transplant (Addenbrooke's Hospital, Cambridge, UK) by centrifugation over ficoll and positive selection using magnetic beads as previously described 20 . The purity of separated cell subsets was determined by three-color flow cytometry. Purified T cells were labeled with 10μM CFSE (Invitrogen) and resuspended in complete RPMI 1640 (Sigma Aldrich) in the presence of 10% FCS. Purified CD8+ T cells (>95%) were then stimulated in sterile, 96-well U-bottomed culture plates (Greiner) using an 'artificial APC' consisting of MACS iBead particles (1:2 bead:cell ratio, Miltenyi) or DynaBead particles (Invitrogen) conjugated to either CD3/CD28 or CD2/CD3/CD28 as indicated in the presence of IL2 (10ng/ml, Gibco life technologies) for 6 days. The magnetic iBead construct was removed after 36h in some instances as indicated. In some experiments, additional costimulation was provided by the addition of either IFNα (10ng/ml, Abcam) or by additional conjugation of recombinant Human PD-L1 Fc Chimera (life technologies, 1μg/ml) or anti-CD40 antibody (50ng/ml, Abcam) as indicated. The nature of costimulatory signals tested was based upon the results of the network analysis of CD4 T cell modules described above (Supplementary Table 2 ).
For restimulation experiments cells were harvested on day 6 post-stimulation and sorted into IL7R hi and IL7R lo populations (Extended Data Figure 6D ) using a FACSAriaIII cell sorter (BD Biosciences) with live/dead discrimination performed using an AquaFluorescent aminereactive dye (Invitrogen). Cell numbers were normalized and were resuspended in complete RPMI 1640 (2×104/ml, Sigma-Aldrich) and 'rested' in a sterile, U-bottomed culture plate (Greiner) for 6 days (37C, 5% CO 2 ) before being restimulated (anti-CD2/3/28 1:2 bead:cell ratio, Miltenyi MACSiBead) for a further 6 days in the presence of IL2 (10ng/ml, Gibco life technologies).
Note that, as described in Extended Data Fig. 6G , human memory CD8 T cell subsets do not equivalently respond to the stimulation conditions described above. As primary whole human CD8 T cells are composed of highly variable proportions of memory subsets and whole CD8 T cells were stimulated it was necessary to perform paired tests of significance when comparing resulting T cell subsets and transcriptional profiles.
Flow cytometry
Immunophenotyping was performed using an LSR Fortessa analyzer (BD Biosciences), and data was analyzed using FlowJo software (Tree Star). Reactions were standardized with multicolor calibration particles (BD Biosciences) with saturating concentrations of the following antibodies: AquaFluorescent Live/Dead (Invitrogen), IL7Rα AF647 (BD biosciences, clone HIL-7R-M21), PDCD1 APC (eBioscience, clone MIH4). For intracellular staining, cells were fixed and permeabilized using a transcription factor staining buffer set (eBioscience) and before staining with saturating concentrations of antibody against BCL2 (BD Biosciences, clone 100). (GSEA FDR q value) of distinct immune signatures between CD8 T cells from melanoma patients, comparing CD8 from tumor-infiltrated lymph node with circulating CD8 T cells 16 .2C ) and also between exhausted CD8 from melanoma-infiltrated lymph node compared to circulating tumorspecific CD8 T cells 16 . Blue = up in exhausted, Red = up in non-exhausted, grey = no significant change (FDR p<0.05). 
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